PL2276495T3 - Stymulacja odpowiedzi układu immunologicznego przez enancjomery kationowych lipidów - Google Patents

Stymulacja odpowiedzi układu immunologicznego przez enancjomery kationowych lipidów

Info

Publication number
PL2276495T3
PL2276495T3 PL09733034T PL09733034T PL2276495T3 PL 2276495 T3 PL2276495 T3 PL 2276495T3 PL 09733034 T PL09733034 T PL 09733034T PL 09733034 T PL09733034 T PL 09733034T PL 2276495 T3 PL2276495 T3 PL 2276495T3
Authority
PL
Poland
Prior art keywords
enantiomers
stimulation
immune response
cationic lipids
lipids
Prior art date
Application number
PL09733034T
Other languages
English (en)
Inventor
Elizabeth Ann Vasievich
Weihsu Chen
Kenya Toney
Gregory Conn
Frank Bedu-Addo
Leaf Huang
Original Assignee
Pds Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pds Biotechnology Corp filed Critical Pds Biotechnology Corp
Publication of PL2276495T3 publication Critical patent/PL2276495T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09733034T 2008-04-17 2009-04-14 Stymulacja odpowiedzi układu immunologicznego przez enancjomery kationowych lipidów PL2276495T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4583708P 2008-04-17 2008-04-17
PCT/US2009/040500 WO2009129227A1 (en) 2008-04-17 2009-04-14 Stimulation of an immune response by enantiomers of cationic lipids
EP09733034.4A EP2276495B1 (en) 2008-04-17 2009-04-14 Stimulation of an immune response by enantiomers of cationic lipids

Publications (1)

Publication Number Publication Date
PL2276495T3 true PL2276495T3 (pl) 2019-05-31

Family

ID=41199446

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09733034T PL2276495T3 (pl) 2008-04-17 2009-04-14 Stymulacja odpowiedzi układu immunologicznego przez enancjomery kationowych lipidów

Country Status (13)

Country Link
US (4) US9789129B2 (pl)
EP (1) EP2276495B1 (pl)
JP (1) JP5971945B2 (pl)
CN (2) CN102137675A (pl)
AU (1) AU2009236306B2 (pl)
BR (1) BRPI0910464B1 (pl)
CA (1) CA2721366C (pl)
ES (1) ES2712505T3 (pl)
IL (1) IL208713A (pl)
PL (1) PL2276495T3 (pl)
RU (1) RU2530555C2 (pl)
TW (1) TWI449534B (pl)
WO (1) WO2009129227A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
ES2712505T3 (es) 2008-04-17 2019-05-13 Pds Biotechnology Corp Estimulación de una respuesta inmunitaria por enantiómeros de lípidos catiónicos
WO2011109294A1 (en) * 2010-03-01 2011-09-09 Dicerna Pharmaceuticals, Inc. Lipid delivery formulations
JP2011184344A (ja) * 2010-03-08 2011-09-22 Kao Corp ｐ２１発現促進剤
CN103327963A (zh) 2010-07-06 2013-09-25 诺华股份有限公司 阳离子水包油乳液
PT3892295T (pt) 2011-05-24 2023-06-01 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Vacinas individualizadas para o cancro
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
AU2012280904B2 (en) 2011-07-06 2017-02-23 Glaxosmithkline Biologicals S.A. Cationic oil-in-water emulsions
TWI673062B (zh) * 2011-09-12 2019-10-01 美商Ｐｄｓ生技公司 粒狀疫苗調配物
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
CA2876656C (en) * 2012-06-15 2023-09-26 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
TWI672149B (zh) * 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
EP4483965A3 (en) 2012-11-28 2025-04-02 BioNTech SE Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
EP3083663A1 (en) * 2013-12-16 2016-10-26 Merck Patent GmbH Survivin-directed cancer vaccine therapy
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
EP3374496A4 (en) * 2015-11-13 2019-07-10 PDS Biotechnology Corporation LIPIDES AS SYNTHETIC VECTORS FOR IMPROVING ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY
JP2019500021A (ja) * 2015-11-13 2019-01-10 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 樹状細胞療法においてｅｘ ｖｉｖｏでの抗原のプロセシングと提示を亢進させるための合成ベクターとしての脂質
US20180221475A1 (en) * 2016-10-05 2018-08-09 Pds Biotechnology Corporation Methods to alter the tumor microenvironment for effective cancer immunotherapy
US10874733B2 (en) * 2016-10-31 2020-12-29 Eyegene Inc. Composition for enhancing immunity comprising immune modulator and cationic liposome, and use of same
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
CA3084957A1 (en) * 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
KR20220114556A (ko) * 2019-11-18 2022-08-17 칠드런'즈 메디컬 센터 코포레이션 암 면역요법을 위한 상주 수지상 세포를 과다활성화시키는 자극제
US20220160867A1 (en) * 2020-11-20 2022-05-26 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for immunotherapy by direct tumor injection
CN120584129A (zh) * 2022-10-19 2025-09-02 Pds生物科技公司 用于治疗表达黏蛋白1蛋白的人癌症的新型t细胞活化免疫治疗

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2167480A (en) 1927-11-02 1939-07-25 Rca Corp Signaling
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
JPS6440808A (en) 1987-08-05 1989-02-13 Canon Kk Zoom lens
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6183745B1 (en) 1990-12-12 2001-02-06 The University Of Queensland Subunit papilloma virus vaccine and peptides for use therein
CA2115364A1 (en) 1991-08-16 1993-03-04 Philip L. Felgner Composition and method for treating cystic fibrosis
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
CA2115839C (en) 1991-08-26 2010-06-01 Maria A. Vitiello Hla-restricted hepatitis b virus ctl epitopes
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
IL105554A (en) 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US7105574B1 (en) 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
WO1995004542A1 (en) 1993-08-06 1995-02-16 Cytel Corporation Cloning and characterization of the complete mage-1 gene
AUPM500494A0 (en) 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
FR2732895B1 (fr) 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
EP0840622A4 (en) 1995-07-21 2003-01-02 Aventis Pharma Inc ADENO-ASSOCIATED VIRUS LIPOSOMES AND THEIR USE FOR THE TRANSFECTION OF DENDRITIC CELLS FOR THE STIMULATION OF SPECIFIC IMMUNITY
CA2259179C (en) 1996-07-03 2008-09-23 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
US7288266B2 (en) 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
US7001614B2 (en) 1996-08-19 2006-02-21 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US20030229040A1 (en) 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
JP2002536344A (ja) 1999-02-05 2002-10-29 ジエンザイム コーポレイション 抗腫瘍免疫を発生させるためのカチオン性脂質の使用
US8206749B1 (en) 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
EP1165140B1 (en) 1999-03-26 2004-08-04 Vical Incorporated Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
WO2000062813A2 (en) 1999-04-20 2000-10-26 The University Of British Columbia Cationic peg-lipids and methods of use
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
US6649170B1 (en) 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
AU782154C (en) 1999-06-10 2006-02-09 Boehringer Ingelheim Animal Health USA Inc. DNA vaccines for pets and sport animals
CA2309313A1 (en) 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
AU785319B2 (en) 1999-09-16 2007-01-11 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
US20030008813A1 (en) 1999-12-17 2003-01-09 Felgner Philip L. Intracellular protein delivery compositions and methods of use
EP1259592A1 (en) 2000-01-11 2002-11-27 Maxygen, Inc. Monocyte-derived dendritic cell subsets
EP1257565A4 (en) * 2000-02-01 2005-04-06 Austin Research Inst DERIVED FROM MUCIN-1 ANTIGENE AND ITS USE IN IMMUNOTHERAPY
AU2001254548B2 (en) 2000-04-20 2006-09-28 The University Of British Columbia Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
ES2307568T3 (es) 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
JP2004537501A (ja) 2001-02-01 2004-12-16 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 肺への遺伝子送達のための安定化ポリマーエアロゾル
EP1425039A4 (en) 2001-03-23 2005-02-02 Us Gov Health & Human Serv PEPTIDES THAT GIVE AN IMMUNE REACTION WITH THE HUMAN PAPILLOMA VIRUS
FR2824326B1 (fr) 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
US7025987B2 (en) 2001-05-30 2006-04-11 The Scripps Research Institute Delivery system for nucleic acids
US20040185057A1 (en) * 2001-06-15 2004-09-23 Kirkby Nikolai Soren Therapeutical vaccination
JP4229832B2 (ja) 2001-06-29 2009-02-25 忠範 真弓 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原とカチオン性リポソームとを含んで成る癌ワクチン
JP2004534088A (ja) * 2001-07-06 2004-11-11 スローン−ケッタリング・インスティテュート・フォア・キャンサー・リサーチ 癌のための多価コンジュゲートワクチン
GB0118517D0 (en) * 2001-07-30 2001-09-19 Mitsubishi Tokyo Pharm Inc Compound
EP1453471B1 (en) 2001-11-07 2011-01-05 Mannkind Corporation Expression vectors encoding epitopes of antigens and methods for their design
US7598421B2 (en) 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
JP4294584B2 (ja) 2002-07-05 2009-07-15 リポクセン・テクノロジーズ・リミテツド 核酸ワクチン接種の免疫応答を高めるための方法
CA2494193A1 (en) 2002-08-12 2004-02-19 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes
US20050031587A1 (en) 2002-10-04 2005-02-10 Yamanouchi Pharmaceutical Co., Ltd. Immune response induction method
JP2006503914A (ja) 2002-10-21 2006-02-02 エムジーアイ ファーマ バイオロジックス インコーポレイテッド ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法
SE0301109D0 (sv) 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
CA2527625A1 (en) 2003-05-30 2004-12-23 Alza Corporation Method of pulmonary administration of an agent
WO2005000889A1 (en) 2003-06-05 2005-01-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides for the treatment of prostate and breast cancer
JP4782675B2 (ja) 2003-06-18 2011-09-28 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム ワクチン接種用スフィンゴイドポリアルキルアミン抱合体
US7906122B2 (en) 2003-06-18 2011-03-15 Yissum Research Development Company Of The Hebrew University Of Jersusalem Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2005014110A1 (en) 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
EP1670509A4 (en) 2003-09-03 2007-10-31 Dendritherapeutics Inc MULTIPLEX VACCINES
CN1609617B (zh) * 2003-09-29 2012-02-15 香港中文大学 诊断与预防严重急性呼吸道综合症（sars）的组合物和方法
ATE502654T1 (de) 2003-12-10 2011-04-15 Canji Inc Verfahren und zusammensetzungen zur behandlung von interferon-resistenten tumoren
CN1559607A (zh) 2004-02-20 2005-01-05 �й�ũҵ��ѧ 一种核酸物质与蛋白质类组合物及其生产方法和在免疫调节中的应用
EP1742659B1 (en) 2004-04-05 2013-03-13 Pah Usa 15 Llc Microfluidized oil-in-water emulsions and vaccine compositions
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
AU2005319716A1 (en) * 2004-06-30 2006-06-29 Id Biomedical Corporation Of Quebec Vaccine compositions for treating coronavirus infection
WO2006007712A1 (en) 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
NZ583157A (en) 2004-12-13 2011-12-22 Leo Lab Ltd Treatment of solid cancers with angeloyl substituted ingenanes
US20060159738A1 (en) * 2004-12-14 2006-07-20 Applera Corporation Cationic liposomes and methods of use
RU2007131689A (ru) 2005-01-21 2009-02-27 Интроджен Тетрапьютикс, Инк. (Us) Местное введение терапевтических и профилактических нуклеиновых кислот, обеспечивающее их пролонгированное действие на клетки-мишени
CA2600370A1 (en) 2005-03-14 2006-09-14 Board Of Regents Of The University Of Texas System Bioactive fus1 peptides and nanoparticle-polypeptide complexes
CN101142851B (zh) 2005-03-18 2012-12-05 唯听助听器公司 助听器的远程控制系统
JP5020935B2 (ja) 2005-04-08 2012-09-05 アルゴス セラピューティクス，インコーポレイティド 樹状細胞組成物および方法
BRPI0609362A2 (pt) 2005-04-11 2010-03-30 Us Gov Health & Human Serv vetor de adenovìrus recombinante, adenovìrus recombinante, composição imunogênica e método para a produção da referida composição imunogênica
US20060275777A1 (en) 2005-06-03 2006-12-07 Waelti Ernst R Novel strategies for protein vaccines
US20070059318A1 (en) 2005-08-15 2007-03-15 Balu-Iyer Sathy V Lipid nano particulates containing antigens as cancer vaccines
US20110305713A1 (en) 2005-10-21 2011-12-15 Medical College Of Georgia Research Institute, Inc Methods and compositions to enhance vaccine efficacy by reprogramming regulatory t cells
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
US8802419B2 (en) * 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
JP2007238559A (ja) 2006-03-10 2007-09-20 Nagoya City Univ 未成熟樹状細胞活性化剤及びその使用
JP2009534332A (ja) 2006-04-21 2009-09-24 トランジェーヌ、ソシエテ、アノニム パピローマウイルスワクチン
US20080014251A1 (en) 2006-07-14 2008-01-17 Advanced Vascular Dynamics Hemostatic compound and its use
EP1894941A1 (en) 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008048976A2 (en) 2006-10-18 2008-04-24 The Government Of The United States Of America As Represented By The Secretary Of The Deparment Of Health And Human Services, Centers For Disease Control And Prevention Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors
KR100817024B1 (ko) 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA2688346A1 (en) 2007-05-23 2008-12-04 Vical Incorporated Compositions and methods for enhancing immune responses to vaccines
US7832751B2 (en) * 2007-06-29 2010-11-16 Harley-Davidson Motor Company Group, Inc. Rear fender assembly
BRPI0818154A2 (pt) 2007-11-02 2020-10-06 The Johns Hopkins University composições de peptídeo de hpv de multitipo e métodos para o tratamento ou prevenção de infecção por papilomavírus humano
ES2712505T3 (es) 2008-04-17 2019-05-13 Pds Biotechnology Corp Estimulación de una respuesta inmunitaria por enantiómeros de lípidos catiónicos
AU2009249403A1 (en) 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
US20100086584A1 (en) 2008-09-18 2010-04-08 Juvaris Biotherapeutics, Inc. VACCINE COMPOSITIONS OF M2e, HA0 AND BM2 MULTIPLE ANTIGENIC PEPTIDES
EP2403527A4 (en) 2009-03-06 2012-11-14 Sinai School Medicine LIVELY WEAKED INFLUENZA VIRUS VACCINES WITH MICRORNA REACTION ELEMENTS
ES2679043T3 (es) 2009-05-15 2018-08-21 Irx Therapeutics, Inc. Inmunoterapia de vacuna
WO2011109294A1 (en) 2010-03-01 2011-09-09 Dicerna Pharmaceuticals, Inc. Lipid delivery formulations
MX2012011300A (es) 2010-03-30 2012-11-29 Sinai School Medicine Vacunas del virus de influenza y usos de las mismas.
EP2567951B1 (en) 2010-04-28 2018-09-19 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
KR20140054140A (ko) 2011-07-27 2014-05-08 베일러 리서치 인스티튜트 췌장암에 대한 수지상 세포(ｄｃ) - 백신 치료요법
TWI673062B (zh) 2011-09-12 2019-10-01 美商Ｐｄｓ生技公司 粒狀疫苗調配物
EP2638896A1 (en) 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
CA2876656C (en) 2012-06-15 2023-09-26 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
TWI672149B (zh) 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
KR20160042935A (ko) 2013-08-21 2016-04-20 큐어백 아게 폐암 치료를 위한 조성물 및 백신
EP3412304A3 (en) 2013-10-23 2019-03-20 The United States of America, as represented by The Secretary, Department of Health and Human Services Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
CN104189897A (zh) 2014-05-21 2014-12-10 深圳先进技术研究院 一种树突状细胞高效负载抗原的制备方法
WO2016146618A1 (en) 2015-03-16 2016-09-22 Max-Delbrück-Centrum für Molekulare Medizin Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library
CN105920599B (zh) 2015-09-17 2020-02-11 武汉生物制品研究所有限责任公司 以阳离子脂质体dotap为佐剂的疫苗及其制备方法
EP3374496A4 (en) 2015-11-13 2019-07-10 PDS Biotechnology Corporation LIPIDES AS SYNTHETIC VECTORS FOR IMPROVING ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY
US20180221475A1 (en) 2016-10-05 2018-08-09 Pds Biotechnology Corporation Methods to alter the tumor microenvironment for effective cancer immunotherapy
MX2019003961A (es) 2016-10-05 2019-08-26 Pds Biotechnology Corp Vacunas novedosas del vph16 con celulas t no restringidas por hla, composiciones y metodos de uso de las mismas.
CA3084957A1 (en) 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
CN111217918B (zh) * 2020-03-04 2020-11-10 中山大学 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗

Also Published As

Publication number Publication date
BRPI0910464B1 (pt) 2021-08-10
US20200330491A1 (en) 2020-10-22
US20110110972A1 (en) 2011-05-12
US20210308157A1 (en) 2021-10-07
US10702541B2 (en) 2020-07-07
CN102137675A (zh) 2011-07-27
TWI449534B (zh) 2014-08-21
IL208713A (en) 2016-10-31
US11801257B2 (en) 2023-10-31
CA2721366A1 (en) 2009-10-22
AU2009236306B2 (en) 2015-04-02
TW201000124A (en) 2010-01-01
RU2530555C2 (ru) 2014-10-10
AU2009236306A1 (en) 2009-10-22
BRPI0910464A2 (pt) 2018-03-27
JP5971945B2 (ja) 2016-08-17
EP2276495A1 (en) 2011-01-26
JP2011518170A (ja) 2011-06-23
WO2009129227A1 (en) 2009-10-22
EP2276495B1 (en) 2018-11-21
RU2010146655A (ru) 2012-05-27
EP2276495A4 (en) 2013-05-15
CN110075113A (zh) 2019-08-02
CA2721366C (en) 2017-06-06
IL208713A0 (en) 2010-12-30
ES2712505T3 (es) 2019-05-13
US20180015114A1 (en) 2018-01-18
US9789129B2 (en) 2017-10-17

Similar Documents

Publication Publication Date Title
IL208713A0 (en) Stimulation of an immune response by enantiomers of cationic lipids
PL2125011T3 (pl) Stymulacja odpowiedzi immunologicznej przez lipidy kationowe
IL233175A0 (en) activation of an immune response
GB201008267D0 (en) Cationic lipids
EP2567952A4 (en) CATIONIC LIPID
ZA201300684B (en) Methods of producing lipids
EP2774912A4 (en) CATIONIC LIPID
EP3431138C0 (en) BRAIN STIMULATION
EP2419172A4 (en) CRANIAL STIMULATION
EP2792368A4 (en) LIPID NANOPARTICLES WITH COMBINATIONS OF CATIONIC LIPIDES
TWM386892U (en) Eye massager
GB201006495D0 (en) Sexual stimulator
PL2789617T3 (pl) Sposób wytwarzania enancjomerów związków spiro-oksyndolowych
PL2354134T3 (pl) Pochodne 2h-chromenowe jako stymulatory receptora 1-fosforanu sfingozyny
GB201709797D0 (en) Novel parasite therapy
IL224381B (en) Application of b-functionalized dihydroxy-chlorins for pdt
GB0906436D0 (en) Circulation Stimulator
SG11201402384TA (en) Vibrating stimulus pad
GB201101591D0 (en) Houysehold appliance subassembly
IL208918A0 (en) Methods of preparing substituted heterocycles-149
EP2252701A4 (en) METHOD FOR IDENTIFYING AN ORGANISM
GB2476767B (en) Method of modifying the immune response
GB2483682B (en) Method of securing fitted furniture
AU2010902717A0 (en) Stimulating immune response
CA3244417A1 (en) Brain stimulation